ABL1 and acute leukemia: The response to therapy should be assessed in the same way as in acute leukemia, following the standards of the respective protocol for morphology, cytogenetics, flow cytometry, and molecular MRD markers including BCR::ABL 1 transcripts by real-time PCR and IgH/TCR markers.